2seventy bio, Inc. appointed new CEO

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


On September 11, 2023, Nick Leschly, the Company's president and chief executive officer, notified the Company's board of directors of his intent to resign as president and chief executive officer upon the Board's identification of his successor.


On September 10, 2023, the board of directors of the Company appointed William D. Baird, III as the chief operating officer of the Company. Mr. Baird will continue to serve as the Company's principal financial officer and principal accounting officer. Mr. Baird, 52, has served as the Company's chief financial officer since 2021. Previously, Mr. Baird served as chief financial officer of bluebird bio, Inc. from February 2019 until November 2021 and served as chief financial officer of Amicus Therapeutics, Inc. from April 2012 until February 2019. Mr. Baird has served on the board of directors of Axcella Health Inc. since June 2018.


There are no (i) family relationships, as defined in Item 401 of Regulation S-K, between Mr. Baird and any of the Company's executive officers or directors, or any person nominated to become a director or executive officer, (ii) arrangements or understandings between Mr. Baird and any other person pursuant to which Mr. Baird was appointed as chief operating officer, or (iii) transactions in which Mr. Baird has an interest requiring disclosure under Item 404(a) of Regulation S-K.